Pernix
Seite 4 von 10 Neuester Beitrag: 25.04.21 02:10 | ||||
Eröffnet am: | 05.02.14 17:36 | von: wallander | Anzahl Beiträge: | 228 |
Neuester Beitrag: | 25.04.21 02:10 | von: Janinauaraa | Leser gesamt: | 45.646 |
Forum: | Hot-Stocks | Leser heute: | 11 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | | 5 | 6 | 7 | 8 | 9 | ... 10 > |
Hauptgründe hierfür:
- extremer Umsatzanstieg seit Q3-2014
- Q4 Umsätze werden 52 Mio. USD sein
- d.h. + 68% zu Q3/14 und +117% zu Q4/2013
- d.h. Q4 KÖNNTE erstmals ein positives net income herauskommen
Und letzter & sehr wichtiger Grund:
- FDA Termin mit priority review am 14.05.15
@ Wallander:
Da du die Aktie schon eine Weile begleitet hast, was war denn der Grund dass die Aktie seit dem Nov/Dez und Ihren Hochs bei 11 USD so zurückgekommen ist ??
Viele Grüße
RobO
Am 25. Februar werden die Q4-Zahlen bekannt gegeben - wichtig wird noch der Ausblick für 2015 (vielleicht Anpassung nach oben?)
Das einzig negative ist der hohe Debt-Bestand, welcher ordentlich Zinsen bedeutet.
Aber hey... wen interessieren heutzutage noch Schulden ;-)
Wachstum ist das A & O.
RobO
Question for the board:
I was going through DD on Pernix and ran into a recent comment by Brean Capital on a Becton Dickinson "deal." Are they referring to a M&A? I went through PTX's history and couldn't find any reference to a deal with Becton Dickinson which makes me think they are in negotiations for a takeover?
I can't imagine Brean Capital would make such a statement up, and also would not see Perella Weinberg Partners involved in any other negotiation between PTX and BD apart from a M&A.
http://bit.ly/1S1q1K7
Perella Weinberg Partners acted for CareFusion when Becton Dickinson acquired it in 2014.
That is the only connection I can find between Becton Dickinson, Pernix, and Perella Weinberg.
http://bit.ly/1S1qVGj
Über ein Buyout wird in den amerikanischen Foren ja schon länger spekuliert...vielleicht wissen die Großen da mal wieder mehr ?!
http://ih.advfn.com/...?pid=nmona&article=71442199&symbol=PTX
Und der Mann wird wohl nicht ohne Grund geholt worden sein...ich sag nur: BUYOUT.
http://www.sedorpharmaceuticals.com/our-team/
fröhlich eingekauft...warum wohl ???
http://zolmax.com/investing/...rapeutics-holdings-inc-ptx/624279.html
Brean Capital Reaffirms “Buy” Rating for Pernix Therapeutics Holdings Inc (PTX)
Pernix Therapeutics Holdings Inc logoBrean Capital reiterated their buy rating on shares of Pernix Therapeutics Holdings Inc (NYSE:PTX) in a report released on Friday, MarketBeat Ratings reports. They currently have a $3.00 price target on the specialty pharmaceutical company’s stock.
A number of large investors recently bought and sold shares of the company. Morgan Stanley increased its stake in Pernix Therapeutics Holdings by 48,456.0% in the fourth quarter. Morgan Stanley now owns 5,160,043 shares of the specialty pharmaceutical company’s stock worth $15,222,000 after buying an additional 5,149,416 shares during the period. Bank of Montreal Can increased its stake in Pernix Therapeutics Holdings by 29.3% in the fourth quarter. Bank of Montreal Can now owns 1,045,279 shares of the specialty pharmaceutical company’s stock worth $3,083,000 after buying an additional 236,832 shares during the period. Millennium Management LLC increased its stake in Pernix Therapeutics Holdings by 150.9% in the fourth quarter. Millennium Management LLC now owns 872,636 shares of the specialty pharmaceutical company’s stock worth $2,574,000 after buying an additional 524,801 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in Pernix Therapeutics Holdings by 17.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,516,585 shares of the specialty pharmaceutical company’s stock worth $1,592,000 after buying an additional 226,151 shares during the period. Finally, Acadian Asset Management LLC increased its stake in Pernix Therapeutics Holdings by 72.9% in the first quarter. Acadian Asset Management LLC now owns 567,542 shares of the specialty pharmaceutical company’s stock worth $595,000 after buying an additional 239,329 shares during the period.
Several other research firms have also issued reports on PTX. Zacks Investment Research lowered shares of Pernix Therapeutics Holdings from a hold rating to a sell rating in a report on Friday, April 15th. Needham & Company LLC lowered shares of Pernix Therapeutics Holdings from a buy rating to a hold rating in a report on Thursday, March 10th. Oppenheimer lowered shares of Pernix Therapeutics Holdings from an outperform rating to a market perform rating in a report on Wednesday, March 16th. S&P Equity Research decreased their price objective on shares of Pernix Therapeutics Holdings from $1.37 to $1.12 in a report on Wednesday, March 23rd. Finally, JMP Securities decreased their price objective on shares of Pernix Therapeutics Holdings from $8.00 to $6.00 and set a market outperform rating for the company in a report on Wednesday, March 2nd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Pernix Therapeutics Holdings has a consensus rating of Hold and a consensus target price of $5.98.
Shares of Pernix Therapeutics Holdings (NYSE:PTX) traded down 17.8074% on Friday, hitting $0.4071. The stock had a trading volume of 4,049,657 shares. The firm’s market capitalization is $24.86 million. Pernix Therapeutics Holdings has a 1-year low of $0.41 and a 1-year high of $7.10. The firm has a 50 day moving average of $0.93 and a 200-day moving average of $2.09.
Pernix Therapeutics Holdings (NYSE:PTX) last released its earnings results on Thursday, May 5th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.36. The firm had revenue of $32.50 million for the quarter, compared to analysts’ expectations of $44.55 million. Equities analysts predict that Pernix Therapeutics Holdings will post ($0.04) earnings per share for the current year.
Pernix Therapeutics Holdings, Inc (NYSE:PTX) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.
Float: 34.49M
% Held by Insiders1: 39.04%
% Held by Institutions1: 58.70%
Shares Short (as of Apr 15, 2016)3: 5.42M
Short Ratio (as of Apr 15, 2016)3: 3.05
Short % of Float (as of Apr 15, 2016)3: 8.85%
Shares Short (prior month)3: 6.12M
http://finance.yahoo.com/q/ks?s=PTX+Key+Statistics
Mal schauen, was morgen Pre-market so passiert...
https://de.finance.yahoo.com/q?s=PTX&ql=0
Gepaart mit der Meldung über Verluste....
Ich denke, dass die 0,40 der neue Boden sind, und hab mir Gestern 4000 für 0,457 in Depot gelegt!
Mit den richtigen News, könnten hier mehrer 100% drinne sein!
Bewertungen liegen ja bei 6,00$ und Institutionen haben ihre Position vergrößert! ;-)
Mal schauen wo die in 1-2 Monaten steht!